FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Spebio

SpePharm announces a claim in excess of 35 million Euros against BioAlliance Pharma for breaking up their Joint-Venture SpeBio

16-Apr-2009 - SpePharm Holding BV announced it intends to file a claim for financial damages and losses of not less than Thirty Five Million Euros against BioAlliance Pharma SA. On February 27th, 2009, less than 9 months after the first commercial launch of Loramyc®, BioAlliance has unilaterally, and in the ...

Denmark Germany joint ventures +2

SpePharm Holding BV Initiates Legal Actions Against BioAlliance Pharma for Breaking Up Joint-Venture SpeBio

05-Mar-2009 - SpePharm Holding BV announced that on February 11th 2009 the Company had initiated a summary proceeding before Dutch courts against BioAlliance Pharma of France. The summary proceeding seeks to prevent BioAlliance from breaking up their joint venture SpeBio. SpeBio BV was established in 2007 for ...

joint ventures oropharyngeal candidiasis

BioAlliance Pharma reacquires the rights to Loramyc in Europe

04-Mar-2009 - BioAlliance Pharma SA announced the termination of the licensing agreement signed in 2007 with SpeBio (a joint venture with SpePharm). The exclusive license in European Union countries other than France covered the distribution of Loramyc®, a muco-adhesive buccal tablet for treating in ...

joint ventures mucositis oncology +1

BioAlliance Pharma establishes new subsidiary, SpeBio, to sell Loramyc in Europe

12-Jun-2007 - BioAlliance Pharma SA announced today that it has established its new subsidiary, SpeBio, to sell its Loramyc(R) product in Europe. The move is in line with the agreement signed on March 8 2007 with Spepharm, joint partner in the venture. The 50:50 joint venture, based in the Netherlands, will ...

joint ventures Netherlands Norway +2